Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406983 | 0.93 | EPHX1 (0.47) | FABP7FABP5CHRM2CHRM4CHRM5 | |
| SCHEMBL6414684 | 0.87 | CACNA1B (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6407549 | 0.79 | CPB1 (0.51) | FFAR4AGTR2ALDH1A1TSHR | |
| SCHEMBL17407791 | 0.79 | CPB1 (0.51) | FFAR4AGTR2ALDH1A1TSHR | |
| SCHEMBL6410593 | 0.79 | FABP7 (0.48) | FABP7FABP5CHRM2CHRM4CHRM5 | |
| SCHEMBL5447182 | 0.78 | FFAR4 (0.57) | FFAR4AGTR2ALDH1A1TSHR | |
| SCHEMBL17391191 | 0.78 | FFAR4 (0.57) | FFAR4AGTR2ALDH1A1TSHR | |
| SCHEMBL5924916 | 0.78 | FFAR4 (0.57) | FFAR4AGTR2ALDH1A1TSHR | |
| SCHEMBL29018749 | 0.78 | FFAR4 (0.57) | FFAR4AGTR2ALDH1A1TSHR | |
| SCHEMBL29188003 | 0.78 | FFAR4 (0.57) | FFAR4AGTR2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | SUMITOMO CHEMICAL COMPAY LIMTED (JP) | 2005-12-29 | — | — | US | disclosed |
| CN-1681767-A | Method for manufacturing 2-(hydroxymethyl) cyclopropane carboxylic acid compound | SUMITOMO CHEMICAL CO (JP) | 2005-10-12 | — | — | CN | disclosed |
| EP-1538141-A1 | PROCESS FOR PRODUCTION OF 2-(HYDROXYMETHYL)CYCLO- PROPANECARBOXYLIC ACIDS | Sumitomo Chemical Company, Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | GRHPR, PCCA, C5 | FABP7 4846/4885FABP5 4727/4885CHRM2 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.